---
title: "Emergent BioSolutions Reports First Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284833924.md"
description: "Gaithersburg-based Emergent BioSolutions Inc. (NYSE: EBS) announced its financial performance for the first quarter ending on March 31, 2026."
datetime: "2026-04-30T20:31:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284833924.md)
  - [en](https://longbridge.com/en/news/284833924.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284833924.md)
---

# Emergent BioSolutions Reports First Quarter 2026 Financial Results

Gaithersburg-based Emergent BioSolutions Inc. (NYSE: EBS) announced its financial performance for the first quarter ending on March 31, 2026.

### Related Stocks

- [EBS.US](https://longbridge.com/en/quote/EBS.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data](https://longbridge.com/en/news/286407513.md)